Who Paid My Doc
Dionne Bell
Nurse Practitioner, Family Baton Rouge, LA Nurse Practitioner
NPI 1588006431 CMS profile 10630656
3140 Florida Blvd, Baton Rouge, LA 70806
General payments
$24,153
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$940
Through program year 2025, Dionne Bell of Baton Rouge, LA is reported in the CMS Open Payments database as having received $24,153 across 178 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $940 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $11,861 | 66 | |
| 2024 | General | $10,997 | 51 | |
| 2023 | General | $475 | 30 | |
| 2022 | General | $330 | 10 | |
| 2021 | General | $491 | 21 |
Beside peers
- Dionne Bell
- Nurse Practitioner, Family median
- Middle half of Nurse Practitioner, Family
- National median
In program year 2025, general payments to Dionne Bell were reported at $11,861. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.
Show as a table
| Year | Dionne Bell | Nurse Practitioner, Family median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $39 | $18–$91 | $163 |
| 2020 | $0 | $32 | $17–$76 | $114 |
| 2021 | $491 | $124 | $35–$379 | $132 |
| 2022 | $330 | $141 | $44–$430 | $149 |
| 2023 | $475 | $154 | $49–$476 | $160 |
| 2024 | $10,997 | $165 | $51–$504 | $164 |
| 2025 | $11,861 | $168 | $53–$521 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 46 drugsPart D claims
1,434
Drug cost
$1,878,382
Branded share of claims
59.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 154 | $602,358 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 51 | $190,457 | |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | Brand | 46 | $153,879 | |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | Brand | 33 | $150,004 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 51 | $144,413 | |
| Tivicay Dolutegravir Sodium | Brand | 43 | $113,368 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 41 | $80,678 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 21 | $71,876 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 18 | $71,821 | |
| Cabenuva Cabotegravir/Rilpivirine | Brand | 22 | $69,356 |
The 10 drugs with the highest cost, of 46 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 6 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Biktarvy |
|
$9,227 | 154 | — |
| DOVATO |
|
$54 | 51 | — |
| Mytesi |
|
$23 | — | — |
| APRETUDE |
|
$18 | — | — |
| PIFELTRO |
|
$10 | 26 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 6 in the dashboard with a free accountRecords
178 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Family in Louisiana
Rebecca Ezell
Nurse Practitioner, Family · Slidell, LA
Erin Pierce
Nurse Practitioner, Family · New Orleans, LA
Tavell Kindall
Nurse Practitioner, Family · New Orleans, LA
Ashlea Hill
Nurse Practitioner, Family · Ruston, LA
Brittany Miller
Nurse Practitioner, Family · Ville Platte, LA
Ryanne Clarke
Nurse Practitioner, Family · Gretna, LA
Related records
Nurse Practitioner, Family in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Family
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.